Not being a scientist type I'm not sure how to answer that Scott. We're still more in the evaluation stage I believe. Once we have the data from this trial from the DMC we'll have a lot more answers.
Cohort 1 (n=5) Kevetrin Cycle - Kevetrin 250 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (750 mg/m2 per week), for 3 weeks (single cycle; total 9 doses); Follow-up for 3 weeks after Kevetrin treatment ends Cohort 2 (n=5) Kevetrin Cycle - Kevetrin 350 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (1050 mg/m2 per week), for 3 weeks (single cycle; total 9 doses); Follow-up for 3 weeks after Kevetrin treatment ends Cohorts 1 and 2 will be conducted in a sequential fashion, with safety data from cohort 1 evaluated by an independent Data Monitoring Committee (DMC). The DMC will make appropriate recommendations based on the available safety data as regards the intent of progressing to the higher dose cohort 2. https://clinicaltrials.gov/ct2/show/NCT03042702?term=cellceutix&rank=2
There is excellent potential as a stand alone and combo therapy because of the way patients tolerate kevetrin thus far though imo. And the action may very well provide full treatment to complete remission. But, like I said, I'm not educated in the field well enough to say. But so far, as much as we know right now, it looks promising.